CA3116015A1 - Amino acid compositions and methods for treating cystic fibrosis - Google Patents

Amino acid compositions and methods for treating cystic fibrosis Download PDF

Info

Publication number
CA3116015A1
CA3116015A1 CA3116015A CA3116015A CA3116015A1 CA 3116015 A1 CA3116015 A1 CA 3116015A1 CA 3116015 A CA3116015 A CA 3116015A CA 3116015 A CA3116015 A CA 3116015A CA 3116015 A1 CA3116015 A1 CA 3116015A1
Authority
CA
Canada
Prior art keywords
cftr
amino acids
free amino
formulation
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3116015A
Other languages
English (en)
French (fr)
Inventor
Sadasivan Vidyasagar
Astrid GROSCHE
Xiaodong Xu
Shanshan LIN
Sreekala PRABHAKARAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Publication of CA3116015A1 publication Critical patent/CA3116015A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3116015A 2018-10-30 2019-10-30 Amino acid compositions and methods for treating cystic fibrosis Pending CA3116015A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752847P 2018-10-30 2018-10-30
US62/752,847 2018-10-30
PCT/US2019/058954 WO2020092639A1 (en) 2018-10-30 2019-10-30 Amino acid compositions and methods for treating cystic fibrosis

Publications (1)

Publication Number Publication Date
CA3116015A1 true CA3116015A1 (en) 2020-05-07

Family

ID=70464502

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3116015A Pending CA3116015A1 (en) 2018-10-30 2019-10-30 Amino acid compositions and methods for treating cystic fibrosis

Country Status (10)

Country Link
US (1) US12220400B2 (https=)
EP (1) EP3873453A4 (https=)
JP (2) JP7689492B2 (https=)
KR (1) KR20210086660A (https=)
CN (1) CN113164425A (https=)
AU (2) AU2019370363B2 (https=)
BR (1) BR112021008395A2 (https=)
CA (1) CA3116015A1 (https=)
MX (1) MX2021005113A (https=)
WO (1) WO2020092639A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3177780A1 (en) * 2020-05-29 2021-12-02 University Of Florida Research Foundation, Inc. Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224071A1 (en) * 1999-08-20 2003-12-04 Howard Murad Pharmaceutical compositions and methods for managing connective tissue ailments
WO2002098405A1 (fr) 2001-06-05 2002-12-12 Ajinomoto Co., Inc. Inhibiteurs de fibrose du foie
ITTO20010804A1 (it) 2001-08-08 2003-02-08 Professional Dietetics Srl Composizioni a base di aminoacidi, idonee alla terapia per la cicatrizzazione e/o riparazione di ferite e lesioni, in particolare per l'appl
WO2003055481A1 (en) 2001-12-25 2003-07-10 Ajinomoto Co., Inc. Organ fibrosis inhibitors
AU2003223718B2 (en) * 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
EP1513870A4 (en) * 2002-05-31 2006-06-07 Childrens Hosp Medical Center CFTR MODIFIER GENES AND EXPRESSED POLYPEPTIDES USEFUL FOR TREATING MUCOVISCIDOSE AND TECHNIQUES AND PRODUCTS FOR DETECTING AND / OR IDENTIFYING THESE
AU2003901316A0 (en) * 2003-03-21 2003-04-03 The Royal Alexandra Hospital For Children Regulation of cell surface proteins
US20040253319A1 (en) * 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
US8389736B2 (en) 2007-10-16 2013-03-05 The Regents Of The University Of California Compounds having activity in correcting mutant-CFTR processing and uses thereof
ITTO20080443A1 (it) 2008-06-06 2009-12-07 Professional Dietetics Srl Composizioni comprendenti amminoacidi, con attivita' pro-angiogenica
EP2664326B1 (en) 2012-05-17 2017-11-01 I.E.R.F.C. European Institute for Cystic Fibrosis Research Combined therapy for cystic fibrosis
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
MA41031A (fr) * 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2016191263A1 (en) 2015-05-22 2016-12-01 Trustees Of Dartmouth College Therapy and kit for the prevention and treatment of cystic fibrosis
CA3001099A1 (en) * 2015-10-09 2017-04-13 Abbvie S.A.R.L. Potentiator-corrector combinations useful in the treatment of cystic fibrosis
MA45397A (fr) * 2016-06-21 2019-04-24 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr

Also Published As

Publication number Publication date
AU2019370363A1 (en) 2021-05-13
JP2022506044A (ja) 2022-01-17
KR20210086660A (ko) 2021-07-08
AU2025248660A1 (en) 2025-10-30
BR112021008395A2 (pt) 2021-09-28
EP3873453A4 (en) 2022-08-03
US12220400B2 (en) 2025-02-11
JP7689492B2 (ja) 2025-06-06
CN113164425A (zh) 2021-07-23
JP2025128185A (ja) 2025-09-02
MX2021005113A (es) 2021-06-15
US20210393584A1 (en) 2021-12-23
AU2019370363B2 (en) 2025-07-10
WO2020092639A1 (en) 2020-05-07
EP3873453A1 (en) 2021-09-08

Similar Documents

Publication Publication Date Title
AU2025248660A1 (en) Amino acid compositions and methods for treating cystic fibrosis
US20110111014A1 (en) Methods and compositions for treatment of neurological disorders
EP2729159B1 (en) Oral treatment of inflammatory bowel disease
HUE031750T2 (en) A method of administering a pulmonary surfactant
AU2025201099A1 (en) Compositions and methods for delivering CFTR polypeptides
WO2019070759A1 (en) AMINO ACID COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
WO2007109648A2 (en) Compositions and methods for modulating store-operated calcium entry
Schwiebert et al. Cystic fibrosis: a multiple exocrinopathy caused by dysfunctions in a multifunctional transport protein
JP2022517255A (ja) 上皮または内皮バリア機能の改善
TR201815345T4 (tr) Nörodejenertif hastalıkların tedavisinde kullanıma yönelik tauroursodeoksikolik asit (tudca).
EP2665485B1 (en) Apolipoprotein aiv as an antidiabetic peptide
Wu et al. CFTR dysfunction leads to defective bacterial eradication on cystic fibrosis airways
AU2002322475B2 (en) Blocking peptide for inflammatory cell secretion
JP7630540B2 (ja) 神経保護ペプチド
WO2018106918A1 (en) Neuronal survival and axonal regeneration through increasing mitochondrial motility
BR112020012972A2 (pt) uso de derivados de álcool 1-fenil-2-piridinil alquílico para tratar fibrose cística
US11028137B2 (en) Mutant islet amyloid polypeptides with improved solubility and methods for using the same
US5834421A (en) Methods and compositions for treating cystic fibrosis
KR20250114044A (ko) 만성 호흡기 질환 치료약
CN118490828A (zh) Oxgr1受体激动剂促进肺黏液纤毛清除系统功能
EP4626441A1 (en) Pharmaceutical combinations and uses thereof
US20190275020A1 (en) Methods and compositions for increasing mucus clearance
Kirjavainen et al. silencing the p27" expression, myosin VIla was labeled immuno
Stern et al. The pathogenesis of cystic fibrosis and progress towards gene therapy
WO2019222800A1 (en) Methods for the treatment or prevention of autoimmune or autoinflammatory diseases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220921

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241024

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241024

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241216

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250414

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250415

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250718

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250718

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251020

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251020

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20251027

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251114

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251208

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251208

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251208